Citations 1
Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase III (P3) overall survival (OS) outcomes using the RECIST 1.1 database.
Mandrekar, Sumithra J. , An, MingâWen , Han, Yu , Group, RECIST Working, Sargent, Daniel J. , Group, RECIST Working
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6600-6600
